Key result
Transcatheter closure of ventricular septal defects with the Amplatzer Membranous VSD Occluder achieved a 91% complete closure rate at 2 years, but caused conduction abnormalities in 20% of patients.
Why the study?
Does transcatheter closure of perimembranous ventricular septal defects with the Amplatzer Membranous VSD Occluder provide effective closure without significant conduction system vulnerability in pediatric patients?
Observational (n=35)
Does transcatheter closure of perimembranous ventricular septal defects with the Amplatzer Membranous VSD Occluder provide effective closure without significant conduction system vulnerability in pediatric patients?
Transcatheter closure of perimembranous VSDs with the Amplatzer occluder is effective but carries a significant 20% risk of conduction abnormalities, emphasizing the vulnerability of the atrioventricular conduction system.
No takes yet. Share an insight, caveat, or question.
Conduction risks warrant caution with this device; leaves open need for randomized trials versus surgery.
Fischer et al. (2007) conducted an observational in ventricular septal defects (n=35). Amplatzer Membranous VSD Occluder was evaluated on complete closure at 2 years. Transcatheter closure of ventricular septal defects with the Amplatzer Membranous VSD Occluder achieved a 91% complete closure rate at 2 years, but caused conduction abnormalities in 20% of patients.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: